Crizotinib for First Line Treatment of ALK or ROS1 Rearrangements

Crizotinib for First Line Treatment of ALK or ROS1 Rearrangements

From: GRACEcast
0 0 4 years ago
00:00
00:55
Medicine, #alk, #cancer, #cancergrace, #chemotherapy, #colorado, #crizotinib, #doublet, #grace, #gracecast, #inhibitor, #lung, #nsclc, #of, #platinum, #rearrangement, #ros1, #ross, #targeted, #therapy, #university
Dr. Ross Camidge, University of Colorado, explains the preference for crizotinib rather than platinum doublet chemotherapy as first line treatment for patients with ALK or ROS1 rearrangements.

Author

cancerGRACE Meetings
cancerGRACE Meetings 2 followers Follow

Find us on Facebook

Spreaker logo
  • Choose Language

For Podcasters and Editors

Tools for Podcasters

For Listeners

Copyright 2021 - Spreaker Inc. a Voxnest Company - Create a Podcast - New York, NY